1. Mexico Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
Corporativo Fragua, S.A.B. de C.V.

Corporativo Fragua, S.A.B. de C.V.

FRAGUAB.MX
Corporativo Fragua, S.A.B. de C.V.MX flagMexican Stock Exchange
467.51
MXN
+7.51
- -
44.76BMarket Cap
Corporativo Fragua, S.A.B. de C.V.
FRAGUAB.MX
(Mexican Stock Exchange)

Recent

price

467.51

P/E

ratio

- -

div

yld

- -

ROIC.AI

2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
TTM
FRC
186.61
206.16
226.48
257.14
281.03
312.21
348.75
395.31
454.8
519.91
603.16
714.65
826.47
954.4
1,066.03
- -
- -
Revenue per Share
5.94
7.12
8.27
8.86
9.39
9.47
9.49
10.73
13.09
14.93
16.67
19.79
25.55
30.98
43.87
- -
- -
Basic EPS, GAAP
6.4
7.72
2.34
2.15
-3.19
-0.15
6.65
4.82
16.79
7.39
26.74
27.19
108.9
48.16
21.96
- -
- -
Free Cash Flow per Basic Share
0.7
0.75
0.78
0.96
1.1
1.2
1.3
1.4
1.5
1.6
2.76
2.94
9.02
9.68
10.7
- -
- -
Dividend per Share
35.27
40.2
9.95
10.54
11.07
11.15
11.17
12.41
14.77
16.61
18.35
21.47
27.23
32.66
45.55
- -
- -
Book Value per Share
41.61
47.64
52.66
60.44
69.34
78.21
87.31
97.7
108.7
121.84
135.76
153.95
168.76
186.32
220.12
- -
- -
Tangible Book Value per Share
103
103
103
103
103
103
103
103
103
103
103
103
103
103
103
- -
- -
Basic Weighted Avg Shares
19,147
21,152
23,237
26,383
28,834
32,033
35,790
40,572
46,674
53,352
61,884
73,314
84,794
97,918
109,374
120,238
73,314
Sales/Revenue/Turnover
4.34
2.24
4.97
4.6
4.42
5
4.56
4.64
5.08
4.85
4.89
2.53
3.31
3.81
4.74
4.03
2.53
Operating Margin (%)
186
251
257
300
365
437
477
436
467
627
724
879
1,130
1,313
1,447
1,539
- -
Depreciation Expense
609
731
849
909
963
972
974
1,102
1,343
1,532
1,710
2,030
2,622
3,179
4,501
4,902
2,030
Net Income, GAAP
23.48
22.61
28.74
22.77
21.65
34.17
35.58
36.59
39.95
36.16
35.12
39.71
43.85
43.36
36.97
34.63
39.71
Effective Tax Rate (%)
3.18
3.46
3.65
3.44
3.34
3.03
2.72
2.72
2.88
2.87
2.76
2.77
3.09
3.25
4.11
4.08
2.77
Profit Margin (%)
1,244
1,536
1,592
1,663
1,366
1,220
1,087
910
1,099
814
1,545
1,563
2,379
2,449
2,989
3,054
1,563
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
513
1,669
1,483
2,067
1,967
1,718
2,015
1,483
LT Debt
4,270
4,888
5,403
6,201
7,115
8,024
8,960
10,027
11,155
12,503
13,929
15,793
17,314
19,116
22,584
25,414
15,793
Total Equity
15.66
7.88
15.67
15.84
14.73
13.63
12.07
12.18
12.86
12.77
12.71
6.23
7.65
9.22
12.86
11.05
6.23
Return on Invested Capital (%)
19.51
20.34
35.05
94.26
97.48
96.46
95.32
100.72
106.73
78.69
57.09
58.53
58.36
59.27
72.48
58.54
58.53
Return on Capital (%)
18.19
18.88
32.98
86.47
86.91
85.26
85.02
91.05
96.3
95.17
95.34
99.4
104.94
103.45
112.18
100.58
99.4
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jun'20
Sep'20
Dec'20
ST Debt
974
957
906
LT Borrowings
676
625
574
LT Finance Leases
796
819
910
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
98
98
98
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Jun'20
Sep'20
Dec'20
Total Current Assets
13,484
14,780
18,151
Cash, Cash Equivalents & STI
1,803
2,402
3,513
Accounts Receivable, Net
148
157
196
Inventories
9,865
10,483
12,586
Total Current Liabilities
12,124
13,250
16,589
Payables & Accruals
- -
- -
- -
ST Debt
974
957
906
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
12.24%
12.82%
12.53%
Free Cash Flow
-400.97%
18.93%
-97.44%
Net Income, GAAP
18.06%
23.92%
8.92%
Sales/Revenue/Turnover
14.17%
14.25%
9.93%
Total Cash Common Dividend
34.76%
49%
14.22%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
97,918
2023
- -
- -
- -
- -
109,374
2024
- -
- -
- -
- -
120,238

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
30.98
2023
- -
- -
- -
- -
43.87
2024
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
9.68
2023
- -
- -
- -
- -
10.7
2024
- -
- -
- -
- -
- -
Similar Companies
Swedish Orphan Biovitrum AB (SOBI.ST)
Sandu Pharmaceuticals Limited (SANDUPHQ.BO)
Scorpius Holdings, Inc. (SCPX)
Grand Pharmaceutical Group Limited (0512.HK)
Accent Microcell Limited (ACCENTMIC.NS)
BIMI International Medical Inc. (BIMI)
Business
Corporativo Fragua, S.A.B. de C.V. (FRAGUAB.MX) operates a chain of Superfarmacia pharmacies in Mexico, offering prescription and over-the-counter medicines; medical devices; personal care and hygiene products; perfumery and cosmetics; grocery items including food, fruits, vegetables, bakery, and packaged beverages; household articles and housewares; electronics and white goods; exercise machines; toys; gifts and accessories; photographic equipment and services such as photo printing, restoration, custom calendars, cups, and albums; as well as pet care products under its own brands for items like chips, bottled water, snacks, and iced tea. The company provides additional services including home delivery, payment of utilities, fines, taxes, catalog orders, and financial services; bread production in partnership with Pan Bueno; and ID photo services across its network of over 1,700 stores in 19 states and more than 144 cities. Founded in 1942 and headquartered in Guadalajara, Jalisco, at Avenida Enrique Díaz de León 261 Norte, the company conducts operations through subsidiaries such as Farmacia Guadalajara S.A. de C.V., Fotosistemas Especializados S.A. de C.V., Organización de Vigilancia Comercial S.A. de C.V., and Operadora SFG S. de R.L. de C.V., serving urban and suburban customers with a focus on accessible healthcare and convenience retail. In recent developments, Corporativo Fragua reported strong financial performance in the second quarter of 2025, with revenue increasing 11% year-over-year to MXN 32.8 billion and net income rising 1.9% to MXN 1.24 billion, driven by organic store expansion and same-store sales growth amid controlled capital expenditures. The company continues its strategy of organic growth, opening new locations such as 24-hour Superfarmacia branches in areas like Jocotepec in early 2025, while enhancing digital capabilities through its mobile app for 24/7 purchases, home delivery in up to 180 minutes, and expanded payment services. No major acquisitions, funding rounds, or strategic alliances were announced in 2024 or 2025; instead, the firm emphasizes internal expansion, distribution center optimizations, and vaccine offerings like updated COVID-19 and influenza shots at select Guadalajara-area stores with on-site medical consultations.